Table 3.

Effect of LN19183 supplementation on participants’ blood pressure and heart rate

Interventions	Measures	Evaluations at
		Pre-dose	60 min	120 min	180 min
Day 1
Placebo (n = 60)	Systolic BP	115± 5	116 ± 6*	117 ± 5*	119 ± 6*
	Diastolic BP	71 ±5	73 ± 5*	73 ± 6*	74 ± 6*
	Heart Rate	70 ± 7	69 ± 6	69 ± 7	70 ± 7
LN19183-450 (n = 60)	Systolic BP	114 ± 5	116 ± 6*	118 ± 6*	119 ± 5*
	Diastolic BP	72 ± 5	74 ± 6*	73 ± 5*	74 ± 5*
	Heart Rate	69 ± 7	69 ± 6	71 ± 8*#	71 ± 8*
Day 2
		Pre-dose	During exercise	20 min post-exercise
Placebo (n = 60)	Systolic BP	115 ± 5	147 ± 5*	119 ± 5*
	Diastolic BP	71 ± 4	73 ± 5*	73 ± 4*
	Heart Rate	71 ± 7	139 ± 10*	75 ± 8*
LN19183-450 (n = 60)	Systolic BP	115 ± 5	146 ± 6*	118 ± 4*
	Diastolic BP	72 ± 4	73 ± 4*	74 ± 4*
	Heart Rate	71 ±7	136 ± 12*	78 ± 10*#

Data present as mean ± SD of the systolic and diastolic blood pressure (BP) in mmHg and heart rate in beats/min.

^*indicates significance (P < 0.05) in intragroup comparison (vs. pre-dose) analyzed using paired t-test.

^#indicates significance (P < 0.05) in intergroup comparison (vs. placebo) analyzed using a mixed model considering treatment, period, and sequence as fixed factors.